Diabetic Eye Screening: Reducing Frequency May Raise Retinal Risks
(MedPage Today) -- Reducing the frequency of eye screening in patients with diabetes from annually to every other year would delay detection of sight-threatening diabetic retinopathy (STDR) and proliferative diabetic retinopathy (PDR), according... (Source: MedPage Today Public Health)
Source: MedPage Today Public Health - October 27, 2023 Category: American Health Source Type: news
FDA Approves Genentech ’s Vabysmo for the Treatment of Retinal Vein Occlusion (RVO)
RVO is the third indication for Vabysmo, in addition to wet, or neovascular, age-related macular degeneration and diabetic macular edema
Approval is based on two Phase III studies demonstrating early and sustained vision improvements that were... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - October 26, 2023 Category: Drugs & Pharmacology Source Type: news
Retinal Artery Occlusion Tied to Higher Risks of Death, Vascular Events
(MedPage Today) -- Credit: CoRus13
Patients with retinal artery occlusions (RAOs) had subsequent increased risks of death, stroke, and myocardial infarction (MI) over both the short and long term compared with matched controls with cataracts... (Source: MedPage Today Cardiovascular)
Source: MedPage Today Cardiovascular - October 26, 2023 Category: Cardiology Source Type: news
What Are Potential Complications of a Forceps Delivery?
Discussion
The main outcome of any delivery is to have a healthy mother and healthy child. For millinea, mothers delivered babies with the help of their mothers and learned women without the benefits of potential instrumented interventions when complications arose, and today they are options for some deliveries. Instrumented delivery techniques have markedly decreased maternal and neonatal morbidity and mortality. Instrument delivery techniques in the second stage of labor includes forceps (begun in the 1600s), vacuum delivery (mainly use began in 1950s) and second stage cesarean section (cesarean section being first used ...
Source: PediatricEducation.org - October 23, 2023 Category: Pediatrics Authors: Pediatric Education Tags: Uncategorized Source Type: news
[Ad hoc announcement pursuant to Art. 53 LR] Roche reports good sales growth despite decline in demand for COVID-19 products
Basel, 19 October 2023Groupsales grow by 1%1at constant exchange rates (CER) in the first nine months, showing a strong increase of 7% in the third quarterExcluding COVID-19 products,Group salesincrease by 9%Pharmaceuticals Division sales grow by 9%, driven by continued high demand for newer medicinesDiagnostics Division ’s base businessincreases by 7%;overall divisional sales are down 18% due to a surge in demand for COVID-19 tests in 2022Highlightsin the third quarter of 2023:EU approval ofEvrysdifor babies under two months old with spinal muscular atrophyFirst approval of subcutaneous form of cancer immunotherapyTecen...
Source: Roche Media News - October 19, 2023 Category: Pharmaceuticals Source Type: news
[Ad hoc announcement pursuant to Art. 53 LR] Roche reports good sales growth despite decline in demand for COVID-19 products
Groupsales grow by 1%1at constant exchange rates (CER) in the first nine months, showing a strong increase of 7% in the third quarterExcluding COVID-19 products,Group salesincrease by 9%Pharmaceuticals Division sales grow by 9%, driven by continued high demand for newer medicinesDiagnostics Division ’s base businessincreases by 7%;overall divisional sales are down 18% due to a surge in demand for COVID-19 tests in 2022Highlightsin the third quarter of 2023:EU approval ofEvrysdifor babies under two months old with spinal muscular atrophyFirst approval of subcutaneous form of cancer immunotherapyTecentriqPositive phase III...
Source: Roche Investor Update - October 19, 2023 Category: Pharmaceuticals Source Type: news
Roche ’s Vabysmo maintained vision improvements with extended treatment intervals up to four months for people with retinal vein occlusion (RVO) in phase III studies
Vabysmo showed robust and sustained retinal drying up to 72 weeks and a safety profile consistent with previous studiesRegulatory applications for Vabysmo in RVO are under review by health authorities around the world; if approved, RVO would be the third indication in addition to nAMD and DMEVabysmo is the first and only treatment that targets and inhibits two signalling pathways linked to a number of vision-threatening retinal conditionsBasel, 10 October 2023 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced positive topline long-term results from the global phase III BALATON and COMINO studies, evaluating extended tre...
Source: Roche Media News - October 10, 2023 Category: Pharmaceuticals Source Type: news
Roche ’s Vabysmo maintained vision improvements with extended treatment intervals up to four months for people with retinal vein occlusion (RVO) in phase III studies
Vabysmo showed robust and sustained retinal drying up to 72 weeks and a safety profile consistent with previous studiesRegulatory applications for Vabysmo in RVO are under review by health authorities around the world; if approved, RVO would be the third indication in addition to nAMD and DMEVabysmo is the first and only treatment that targets and inhibits two signalling pathways linked to a number of vision-threatening retinal conditionsBasel, 10 October 2023 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced positive topline long-term results from the global phase III BALATON and COMINO studies, evaluating extended tre...
Source: Roche Investor Update - October 10, 2023 Category: Pharmaceuticals Source Type: news
Demand for Anti-VEGF Injections for Retinal Diseases Expected to Surge
(MedPage Today) -- The demand for intravitreal vascular endothelial growth factor (VEGF) inhibitor therapy is forecasted to increase by about 50% over the next 5 years in Denmark, due largely to an aging population, a nationwide cohort study showed... (Source: MedPage Today Primary Care)
Source: MedPage Today Primary Care - October 9, 2023 Category: Primary Care Source Type: news
The Impact of AI on Retinal Disease Management The Impact of AI on Retinal Disease Management
This article explores the potential of AI-enabled devices in the management of retinal conditions and provides recommendations for the use of this technology.Current Opinion in Ophthalmology (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - October 6, 2023 Category: Consumer Health News Tags: Ophthalmology Journal Article Source Type: news
Roche to present new key clinical and real-world data at ECTRIMS-ACTRIMS 2023 showcasing strength of long-term outcomes in MS and NMOSD
Late-breaking results from Phase III trial of OCREVUS (ocrelizumab) subcutaneous injection and Phase II trial of BTK inhibitorfenebrutinib in multiple sclerosis (MS) will be presented10-year OCREVUS efficacy and safety data show significant benefit in slowing long-term disability progression and consistent long-term safety profile in MSAdditional OCREVUS real-world and clinical data show impact for underrepresented populations including more than 3,200 pregnant women and Black and Hispanic/Latinx patients with MSLonger-term safety data and late-breaking efficacy data from Phase III trial of ENSPRYNG (satralizumab) inneurom...
Source: Roche Media News - October 2, 2023 Category: Pharmaceuticals Source Type: news
Roche to present new key clinical and real-world data at ECTRIMS-ACTRIMS 2023 showcasing strength of long-term outcomes in MS and NMOSD
Late-breaking results from Phase III trial of OCREVUS (ocrelizumab) subcutaneous injection and Phase II trial of BTK inhibitorfenebrutinib in multiple sclerosis (MS) will be presented10-year OCREVUS efficacy and safety data show significant benefit in slowing long-term disability progression and consistent long-term safety profile in MSAdditional OCREVUS real-world and clinical data show impact for underrepresented populations including more than 3,200 pregnant women and Black and Hispanic/Latinx patients with MSLonger-term safety data and late-breaking efficacy data from Phase III trial of ENSPRYNG (satralizumab) inneurom...
Source: Roche Investor Update - October 2, 2023 Category: Pharmaceuticals Source Type: news
AI System Outperforms Standard Review of Imaging for Retinal Disease
(MedPage Today) -- Review of screening retinal images for diabetic retinopathy by an artificial intelligence (AI) system demonstrated potential for significantly reducing the need for manual review with no loss in accuracy, according to a large... (Source: MedPage Today Endocrinology)
Source: MedPage Today Endocrinology - September 26, 2023 Category: Endocrinology Source Type: news
Retinal changes associated with football-related concussions and head impacts - Atlas JB, Young M, Bertolace L, Juskiewicz I, Abrham Y, Merchant-Borna K, Dermady S, Keane B, Ramchandran RS, Bazarian J, Silverstein S.
This pilot study explored the sensitivity of retinal markers to CNS sequelae of concussive and subconcussive head hits. Three groups of college athletes were assessed at pre-season, post-season and 4-months later: Football players with a concussion history... (Source: SafetyLit)
Source: SafetyLit - September 25, 2023 Category: International Medicine & Public Health Tags: Ergonomics, Human Factors, Anthropometrics, Physiology Source Type: news
